BNB Plus Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Clay D. Shorrock
- Full Time Employees
- 26
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Health Sciences Drive Stony Brook NY United States of America 11790
- IPO Date
- Oct 8, 2025
- CIK
- 0000744452
- Website
- bnbx.io
- Similar Companies
- Business
- BNB Plus Corp. (NASDAQ: BNBX), formerly Applied DNA Sciences, Inc., develops and commercializes molecular technologies focused on DNA manufacturing, therapeutics, and supply chain security; its core offerings include the proprietary LinearDNA™ platform for scalable, cell-free production of plasmid DNA and messenger RNA for gene and cell therapies, DNA-based tagging and authentication solutions such as Signature® DNA markers for anti-counterfeiting and traceability in textiles, pharmaceuticals, and currency; and diagnostic testing services including PCR-based assays for cotton fiber purity and pathogen detection. The company operates primarily in the biotechnology and diagnostics sectors, serving pharmaceutical and biotech firms, textile manufacturers, law enforcement agencies, and government entities across North America, Europe, and Asia. Founded in 2003 and headquartered in Stony Brook, New York, BNB Plus Corp. recently rebranded from Applied DNA Sciences, Inc. and elected Josh Kruger as Chairman of the Board, signaling a strategic pivot toward expanded molecular therapeutics capabilities amid ongoing advancements in its DNA manufacturing technologies.
BNB Plus Corp. (BNBX) Announces Nasdaq Delisting Determination and Transition to OTCQB Market; Company to Seek Review by Nasdaq Listing and Hearing Review Council
BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing
BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order
BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value
20/20 Biolabs (NASDAQ:AIDX) and Applied Dna Sciences (NASDAQ:BNBX) Head to Head Survey
Analyzing Applied Dna Sciences (NASDAQ:BNBX) & 20/20 Biolabs (NASDAQ:AIDX)
Contrasting Applied Dna Sciences (NASDAQ:BNBX) and 20/20 Biolabs (NASDAQ:AIDX)
Comparing 20/20 Biolabs (NASDAQ:AIDX) & Applied Dna Sciences (NASDAQ:BNBX)
Financial Contrast: Applied Dna Sciences (NASDAQ:BNBX) vs. 20/20 Biolabs (NASDAQ:AIDX)
20/20 Biolabs (NASDAQ:AIDX) vs. Applied Dna Sciences (NASDAQ:BNBX) Critical Analysis
Reviewing Applied Dna Sciences (NASDAQ:BNBX) and 20/20 Biolabs (NASDAQ:AIDX)
20/20 Biolabs (NASDAQ:AIDX) vs. Applied Dna Sciences (NASDAQ:BNBX) Head-To-Head Analysis
Comparing Applied Dna Sciences (NASDAQ:BNBX) and 20/20 Biolabs (NASDAQ:AIDX)
Reviewing 20/20 Biolabs (NASDAQ:AIDX) and Applied Dna Sciences (NASDAQ:BNBX)
Financial Survey: 20/20 Biolabs (NASDAQ:AIDX) vs. Applied Dna Sciences (NASDAQ:BNBX)
Reviewing 20/20 Biolabs (NASDAQ:AIDX) and Applied Dna Sciences (NASDAQ:BNBX)
Critical Contrast: Applied Dna Sciences (NASDAQ:BNBX) vs. 20/20 Biolabs (NASDAQ:AIDX)
BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform
Contrasting Applied Dna Sciences (NASDAQ:BNBX) and 20/20 Biolabs (NASDAQ:AIDX)
Applied Dna Sciences (NASDAQ:BNBX) vs. 20/20 Biolabs (NASDAQ:AIDX) Financial Survey